European Society for Paediatric Endocrinology consensus guidelines on screening, diagnosis, and management of congenital hypothyroidism.
Léger J, Olivieri A, Donaldson M, Torresani T, Krude H, van Vliet G, Polak M, Butler G, ESPE-PES-SLEP-JSPE-APEG-APPES-ISPAE, Congenital Hypothyroidism Consensus Conference Group. · 2014
Read European Society for Paediatric Endocrinology consensus guidelines on screening, diagnosis, and management of congenital hypothyroidism. by Léger J, Olivieri A, Donaldson M, Torresani T, Krude H, van Vliet G, Polak M, Butler G, ESPE-PES-SLEP-JSPE-APEG-APPES-ISPAE, Congenital Hypothyroidism Consensus Conference Group. (2014) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4207909.txt.
Introduction
Juliane Léger and seven co-authors issued European consensus guidelines on congenital hypothyroidism in the Journal of Clinical Endocrinology and Metabolism in 2014. Babies born with too little thyroid hormone face stunted brain development unless treatment starts fast. Practice varied across countries, so the European Society for Paediatric Endocrinology gathered 32 experts from six societies to agree on shared rules.
The guidelines back screening every newborn, then quick work to find the cause and severity. Treatment with levothyroxine should start at once, with frequent checks to keep hormone levels in range. Children suspected of a passing form should get a trial off treatment later. Regular checks of development and hearing, plus parent education, complete the plan. The document harmonizes care across the societies involved.
Catalog record
| CREATOR | Léger J, Olivieri A, Donaldson M, Torresani T, Krude H, van Vliet G, Polak M, Butler G, ESPE-PES-SLEP-JSPE-APEG-APPES-ISPAE, Congenital Hypothyroidism Consensus Conference Group. |
|---|---|
| YEAR | 2014 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 105 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
European Society for Paediatric Endocrinology Consensus Guidelines on Screening, Diagnosis, and Management of Congenital Hypothyroidism By Juliane Léger, Antonella Olivieri, Malcolm Donaldson, Toni Torresani, Heiko Krude, Guy van Vliet, Michel Polak, Gary Butler Published in: The Journal of Clinical Endocrinology and Metabolism DOI: 10.1210/jc.2013-1891 ABSTRACT Objective: The aim was to formulate practice guidelines for the diagnosis and management of congenital hypothyroidism (CH). Evidence: A systematic literature search was conducted to identify key articles relating to the screening, diagnosis, and management of CH. The evidence-based guidelines were developed with the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system, describing both the strength of recommendations and the quality of evidence. In the absence of sufficient evidence, conclusions were based on expert opinion. Consensus Process: Thirty-two participants drawn from the European Society for Paediatric Endocrinology and five other major scientific societies in the field of pediatric endocrinology were allocated to working groups with assigned topics and specific questions. Each group searched the literature, evaluated the evidence, and developed a draft document. These papers were debated and finalized by each group before presentation to the full assembly for further discussion and agreement. Recommendations: The recommendations include: worldwide neonatal screening, approaches to assess the cause (including genotyping) and the severity of the disorder, the immediate initiation of appropriate L-T4 supplementation and frequent monitoring to ensure dose adjustments to keep thyroid hormone levels in the target ranges, a trial of treatment in patients suspected of transient CH, regular assessments of developmental and neurosensory functions, consulting health professionals as appropriate, and education about CH. The harmonization of diagnosis, management, and routine health surveillance would not only optimize patient outcomes, but should also facilitate epidemiological studies of the disorder. Individuals with CH require monitoring throughout their lives, particularly during early childhood and pregnancy. SUMMARY OF RECOMMENDATIONS 1.1 The benefits of congenital hypothyroidism screening - Early detection and treatment of congenital hypothyroidism (CH) through neonatal screening prevents neurodevelopmental disability and optimizes developmental outcomes (1|⊕⊕⊕). 1.2 Analytical methodology, effectiveness, and efficacy of CH screening strategies - Screening for primary CH should be introduced worldwide. The initial priority of neonatal screening for CH should be the detection of all forms of primary CH: mild, moderate, and severe. The most sensitive test for detecting primary CH is TSH determination (1|⊕⊕⊕). 1.3 Screening in special categories of neonates at risk of CH - A strategy of second screening should be considered for the following conditions: preterm neonates; low-birth weight (LBW) and very low-birth weight (VLBW) neonates; ill and preterm newborns admitted to neonatal intensive care units (NICU); specimen collection within the first 24 hours of life; and multiple births (particularly same-sex twins); (2|⊕⊕○). 2.1 Biochemical criteria used in the decision to initiate treatment - If capillary TSH concentration from blood obtained on neonatal screening is ≥ 40 mU/L whole blood, we recommend starting treatment as soon as a good venous sample can be obtained, without waiting for the venous blood test result, unless venous thyroid function test (TFT) results are available on the same day (1|⊕⊕○). - If capillary TSH concentration is < 40 mU/l of whole blood, the clinician may wait for the results of venous TFT, provided that these results are available on the following day (1|⊕⊕○). 2.2 Communication of elevated TSH result - The detection of a high TSH concentration on screening should be communicated by an experienced person (eg screening laboratory staff or pediatric endocrine team) either by telephone or in person (2|⊕○○). - When the child reaches nursery or school age, educators and teachers need not be informed about the child having CH to avoid stigmatization due to “labeling” (2|⊕○○). 2.3 Decision to start treatment on the basis of venous TFTs - If venous free T4 (FT4) concentration is below norms for age, treatment should be started immediately (1|⊕⊕⊕). - If venous TSH concentration is > 20 mU/L, treatment should be started, even if FT4 concentration is normal (2|⊕⊕○). - If venous TSH concentration is ≥ 6 to 20 mU/l beyond 21 days in a well baby with a FT4 concentration within the limits for age, we suggest a) investigation, which should include diagnostic imaging, to try to obtain a definitive diagnosis; b) consideration, in discussion with the family, of either initiating thyroxine supplementation immediately and retesting, off treatment, at a later stage; or withholding treatment but retesting two weeks later (2|⊕⊕○). 2.4 Use of imaging in assessing the severity and cause of CH - X-ray of the knee may be carried out to assess the severity of intrauterine hypothyroidism by the presence or absence of femoral and tibial epiphyses (2|⊕⊕⊕). - The thyroid gland should be imaged using either radioisotope scanning (scintigraphy) with or without the perchlorate discharge test; or ultrasonography; or both (1|⊕⊕○). - Imaging should never be allowed to delay the initiation of treatment (1|⊕⊕○). 2.5 Associated malformations and syndromes - All neonates with high TSH concentrations should be examined carefully for congenital malformations (particularly cardiac) and for dysmorphic features (1|⊕⊕⊕). 3.1 Treatment and monitoring of CH - L-T4 alone is recommended as the medication of choice for treating CH (1|⊕⊕○). - L-T4 treatment should be initiated as soon as possible and no later than 2 weeks after birth or immediately after confirmatory serum test results in infants in whom CH is detected by a second routine screening test (1|⊕⊕○). - An initial L-T4 dose of 10–15 μg/kg per day should be given (1|⊕⊕○). - Infants with severe disease, as defined by a very low pretreatment TT4 or FT4 concentration, should be treated with the highest initial dose (1|⊕⊕○). - L-T4 should be administered orally; if intravenous treatment is necessary the dose should be no more than 80% of the oral dose, The dose should then be adjusted according to TSH and FT4 determinations (1|⊕⊕○). - L-T4 tablets should be crushed and administered via a small spoon, in a few milliliters of water or breast milk (1|⊕⊕○). - Brand rather than generic L-T4 tablets should be used, particularly during infancy and in severe cases (2|⊕⊕○). - L-T4 liquid should only be used if pharmaceutically produced (1|⊕⊕○). - Parents should be provided with written instructions on L-T4 treatment (1|⊕○○). 3.2 Monitoring of dose and follow-up - Serum or plasma FT4 (or TT4) and TSH concentrations should be determined at least 4 hours after the last L-T4 administration (1|⊕⊕○). - TSH concentration should be maintained in the age-specific reference range; TT4 or FT4 concentration should be maintained in the upper half of the age-specific reference range (1|⊕⊕○). - Any reduction of L-T4 dose should not be based on a single increase in FT4 concentration during treatment (1|⊕⊕○). - The first follow-up examination should take place 1–2 weeks after the start of L-T4 treatment (1|⊕○○). - Subsequent evaluation should take place every 2 weeks until a complete normalization of TSH concentration is reached; then every 1 to 3 months thereafter until the age of 12 months (1|⊕○○). Between the ages of one and three years, children should undergo frequent clinical and laboratory evaluations (every 2 to 4 months) (1|⊕○○). Thereafter, evaluations should be carried out every 3 to 12 months until growth is completed (1|⊕○○). - More frequent evaluations should be carried out if compliance is questioned